Ablative Endoscopic Therapies for Barrett's-Esophagus-Related Neoplasia

Gastroenterology Clinics of North America

Volumn 44, Issue 2, 2015, Pages 337-353

  Peter, Shajan ^a   Mönkemüller, Klaus ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Barrett's esophagus; Cryoablation; Dysplasia; Neoplasia; Photodynamic therapy; Radiofrequency ablation

Indexed keywords

CARBON DIOXIDE; LIDOCAINE; LIQUID NITROGEN; PARACETAMOL; PHOTOSENSITIZING AGENT; PROTON PUMP INHIBITOR; SUCRALFATE;

ABLATION DEVICE; ARGON PLASMA COAGULATION; BALLOON CATHETER; BARRETT ESOPHAGUS; BLEEDING; CRYOABLATION; DYSPHAGIA; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS DYSPLASIA; FEVER; FOLLOW UP; HUMAN; INTESTINE METAPLASIA; PATIENT SELECTION; PHOTODYNAMIC THERAPY; RADIOFREQUENCY ABLATION; REVIEW; THORAX PAIN; ADENOCARCINOMA; CATHETER ABLATION; CRYOSURGERY; ESOPHAGEAL NEOPLASMS; PATIENT CARE PLANNING; PHOTOCHEMOTHERAPY; PREOPERATIVE CARE; PROCEDURES;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CATHETER ABLATION; CRYOSURGERY; ESOPHAGEAL NEOPLASMS; HUMANS; PATIENT CARE PLANNING; PHOTOCHEMOTHERAPY; PREOPERATIVE CARE;

EID: 84929912667     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.02.014     Document Type: Review

References (71)

1. Shaheen N.J., Crosby M.A., Bozymski E.M., et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 2000, 119:333-338.
2. Hvid-Jensen F., Pedersen L., Drewes A.M., et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. NEngl J Med 2011, 365:1375-1383.
3. American Gastroenterological Association, Spechler S.J., Sharma P., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091.
4. Desai T.K., Krishnan K., Samala N., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61:970-976.
5. Wani S., Falk G., Hall M., et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011, 9:220-227. [quiz: e26].
6. Spechler S.J., Souza R.F. Barrett's esophagus. NEngl J Med 2014, 371:836-845.
7. Zagari R.M., Fuccio L., Wallander M.A., et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008, 57:1354-1359.
8. Taylor J.B., Rubenstein J.H. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol 2010, 105:1729. 1730-7. [quiz: 38].
9. Ronkainen J., Talley N.J., Storskrubb T., et al. Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol 2011, 106:1946-1952.
10. Rastogi A., Puli S., El-Serag H.B., et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008, 67:394-398.
11. Spechler S.J. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013, 310:627-636.
12. Kong C.Y., Kroep S., Curtius K., et al. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev 2014, 23:997-1006.
13. Sarosi G., Brown G., Jaiswal K., et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 2008, 21:43-50.
14. Leggett C.L., Gorospe E.C., Wang K.K. Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma. Gastroenterol Clin North Am 2013, 42:175-185.
15. Pouw R.E., Gondrie J.J., Rygiel A.M., et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am J Gastroenterol 2009, 104:1366-1373.
16. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006, 131:1392-1399.
17. Levine D.S., Haggitt R.C., Blount P.L., et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993, 105:40-50.
18. ASGE Standards of Practice Committee, Evans J.A., Early D.S., et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012, 76:1087-1094.
19. van Vilsteren F.G., Phoa K.N., Alvarez Herrero L., et al. Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase. Clin Gastroenterol Hepatol 2013, 11:491-498.e1.
20. van Vilsteren F.G., Phoa K.N., Alvarez Herrero L., et al. Asimplified regimen for focal radiofrequency ablation of Barrett's mucosa: a randomized multicenter trial comparing two ablation regimens. Gastrointest Endosc 2013, 78:30-38.
21. Peter S., Wilcox C.M., Monkemuller K. Radiofrequency ablation of Barrett's esophagus with the channel RFA endoscopic catheter. Gastrointest Endosc 2014, 79:1034-1035.
22. Allen B., Kapoor N., Willert R., et al. Endoscopic ablation of Barrett's neoplasia with a new focal radiofrequency device: initial experience with the Halo60. Endoscopy 2012, 44:707-710.
23. Fitzgerald R.C., Rubenstein J.H. Oracular guidance on clinical management of early neoplastic Barrett's esophagus. Gastroenterology 2012, 143:282-284.
24. Shaheen N.J., Sharma P., Overholt B.F., et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. NEngl J Med 2009, 360:2277-2288.
25. Shaheen N.J., Overholt B.F., Sampliner R.E., et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011, 141:460-468.
26. Gupta M., Iyer P.G., Lutzke L., et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology 2013, 145:79-86 e1.
27. Wolf W.A., Dellon E.S., Shaheen N.J. Esophageal diseases. Gastrointest Endosc 2014, 80:374-379.
28. Wolf W.A., Pruitt R.E., Ertan A., et al. Sa1452 Predictors of Esophageal Adenocarcinoma in Patients With Prior Radiofrequency Ablation (RFA) for Treatment of Barrett's Esophagus: Results From the U.S. RFA Registry. Gastrointest Endosc 2014, 79:AB217.
29. Dunbar K.B. Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus. Curr Opin Gastroenterol 2013, 29:446-453.
30. Bulsiewicz W.J., Kim H.P., Dellon E.S., et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus. Clin Gastroenterol Hepatol 2013, 11:636-642.
31. Akiyama J., Marcus S.N., Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus. Dig Dis Sci 2012, 57:2625-2632.
32. Krishnan K., Pandolfino J.E., Kahrilas P.J., et al. Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012, 143:576-581.
33. Korst R.J., Santana-Joseph S., Rutledge J.R., et al. Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett's esophagus. JThorac Cardiovasc Surg 2013, 145:1529-1534.
34. Pasricha S., Bulsiewicz W.J., Hathorn K.E., et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. Clin Gastroenterol Hepatol 2014, 12:1840-1847.e1.
35. Zemlyak A.Y., Pacicco T., Mahmud E.M., et al. Radiofrequency ablation offers a reliable surgical modality for the treatment of Barrett's esophagus with a minimal learning curve. Am Surg 2012, 78:774-778.
36. Fudman D.I., Lightdale C.J., Poneros J.M., et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointest Endosc 2014, 80:71-77.
37. Sharma V.K. Ablation of Barrett's esophagus using the HALO radiofrequency ablation system. Tech Gastrointest Endosc 2010, 12:26-34.
38. van Vilsteren F.G., Bergman J.J. Endoscopic therapy using radiofrequency ablation for esophageal dysplasia and carcinoma in Barrett's esophagus. Gastrointest Endosc Clin N Am 2010, 20:55-74. vi.
39. Gray N.A., Odze R.D., Spechler S.J. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol 2011, 106:1899-1908. [quiz: 909].
40. Greenwald B.D., Dumot J.A. Cryotherapy for Barrett's esophagus and esophageal cancer. Curr Opin Gastroenterol 2011, 27:363-367.
41. Shaheen N.J., Greenwald B.D., Peery A.F., et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010, 71:680-685.
42. Gosain S., Mercer K., Twaddell W.S., et al. Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc 2013, 78:260-265.
43. Greenwald B.D., Dumot J.A., Abrams J.A., et al. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Gastrointest Endosc 2010, 71:686-693.
44. Dunn J.M., Mackenzie G.D., Banks M.R., et al. Arandomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus. Lasers Med Sci 2013, 28:707-715.
45. Overholt B.F., Lightdale C.J., Wang K.K., et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005, 62:488-498.
46. Overholt B.F., Wang K.K., Burdick J.S., et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007, 66:460-468.
47. Ertan A., Zaheer I., Correa A.M., et al. Photodynamic therapy vs radiofrequency ablation for Barrett's dysplasia: efficacy, safety and cost-comparison. World J Gastroenterol 2013, 19:7106-7113.
48. Rees J.R., Lao-Sirieix P., Wong A., et al. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010, (1). CD004060.
49. Kim H.P., Bulsiewicz W.J., Cotton C.C., et al. Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe compared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia. Gastrointest Endosc 2012, 76:733-739.
50. Bennett C., Vakil N., Bergman J., et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012, 143:336-346.
51. Haidry R.J., Dunn J.M., Butt M.A., et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013, 145:87-95.
52. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014, 63:7-42.
53. Prasad G.A., Buttar N.S., Wongkeesong L.M., et al. Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol 2007, 102:2380-2386.
54. Hur C., Choi S.E., Rubenstein J.H., et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012, 143:567-575.
55. Inadomi J.M., Somsouk M., Madanick R.D., et al. Acost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009, 136:2101-2114.e1-6.
56. Shaheen N.J., Peery A.F., Hawes R.H., et al. Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus. Endoscopy 2010, 42:790-799.
57. Wani S., Falk G.W., Post J., et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011, 141:1179-1186. 1186.e1.
58. Bhat S., Coleman H.G., Yousef F., et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. JNatl Cancer Inst 2011, 103:1049-1057.
59. Curvers W.L., ten Kate F.J., Krishnadath K.K., et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010, 105:1523-1530.
60. Almond L.M., Hodson J., Barr H. Meta-analysis of endoscopic therapy for low-grade dysplasia in Barrett's oesophagus. Br J Surg 2014, 101:1187-1195.
61. Phoa K.N., van Vilsteren F.G., Weusten B.L., et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 2014, 311:1209-1217.
62. Monkemuller K. Radiofrequency ablation for Barrett esophagus with confirmed low-grade dysplasia. JAMA 2014, 311:1205-1206.
63. Spechler S.J., Sharma P., Souza R.F., et al. American Gastroenterological A. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140:e18-52. [quiz: e13].
64. Spechler S.J. Barrett's esophagus without dysplasia: wait or ablate?. Dig Dis Sci 2011, 56:1926-1928.
65. Dunbar K.B., Spechler S.J. Controversies in Barrett esophagus. Mayo Clin Proc 2014, 89:973-984.
66. Gregson E.M., Fitzgerald R.C. Biomarkers for dysplastic Barrett's: ready for prime time?. World J Surg 2014, 39(3):568-577.
67. Prasad G.A., Bansal A., Sharma P., et al. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010, 105:1490-1502.
68. Prasad G.A., Wang K.K., Halling K.C., et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008, 135:370-379.
69. Timmer M.R., Brankley S.M., Gorospe E.C., et al. Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointest Endosc 2014, 80:984-991.
70. Shaheen N.J., Kim H.P., Bulsiewicz W.J., et al. Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry. JGastrointest Surg 2013, 17:21-28. [discussion: p. 28-9].
71. Frantz D.J., Dellon E.S., Shaheen N.J. Radiofrequency ablation of Barrett's esophagus. Tech Gastrointest Endosc 2010, 12:100-107.